Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study

BACKGROUND: The metabolism of many proton pump inhibitors is influenced by CYP2C19 genotype, which is a limitation of their use. OBJECTIVES: To determine the efficacy and safety profile of Z-215 (azeloprazole sodium) as initial treatment for reflux esophagitis (RE), dose response, and optimal dose c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinoshita, Yoshikazu, Kusano, Motoyasu, Iwakiri, Katsuhiko, Fujishiro, Mitsuhiro, Tachikawa, Naoto, Haruma, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054772/
https://www.ncbi.nlm.nih.gov/pubmed/30038671
http://dx.doi.org/10.1016/j.curtheres.2018.03.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054772/
https://www.ncbi.nlm.nih.gov/pubmed/30038671
http://dx.doi.org/10.1016/j.curtheres.2018.03.004

Ejemplares similares